溶剂对SEBS/PMMA共混物薄膜形态的影响

采用原子力显微镜研究了聚（苯乙烯嵌-乙烯／丁烯嵌-苯乙烯）（SEBS）和聚甲基丙烯酸甲酯（PMMA）共混物不同溶剂旋转涂膜的表面形态和相分离行为。结果表明，用共混物的氯仿溶液旋转涂膜，可见明显的共混物的宏观相分离和SEBS的微观相分离形态。改变选择性溶剂可使旋涂膜具有不同的均匀度和形态结构，其相区的尺寸和形状相差甚大，有海岛型、网状、双连续状结构。AFM显示用环己烷／丁酮混合溶剂旋转涂膜，共混物的相分离最为彻底；用选择性溶剂氯仿时次之，但有明显的相分离；对SEBS和PMMA均无选择性的单一溶剂或混合溶剂则无明显相分离。     

PLLA/PMMA共混制备多孔膜

以聚甲基丙烯酸甲酯（PMMA）和左旋聚乳酸（PLLA）为原料,制备了二者的共混膜。利用差示扫描量热仪（DSC）研究了PLLA/PMMA共混膜的相容性,发现该体系为部分互容。在此基础上,利用碱液降解共混膜中的PLLA,从而制备多孔膜。结果发现,聚合物组成的改变对多孔膜的细节结构有明显影响。当PLLA与PMMA质量比为25/75时,主体膜主要由颗粒和纤维结构构成;当PLLA与PMMA质量比为50/50及75/25时,主体膜明显由颗粒状结构形成,其尺寸为60~100 nm。由此可见,利用PLLA/PMMA的共混膜及碱液降解法可方便地制备多孔聚合物膜。     

甲基丙烯酸甲酯改性聚醚聚氨酯的结构形态与力学性能

采用同步法合成了聚氨酯(PU)/聚甲基丙烯酸甲酯(PMMA)的线型共混物、嵌段共聚物和互穿高聚物(IPN)。凭藉力学性能测试、电镜观察和动态力学谱分析,研究了光固化、热固化、化学组成、物理结构等因素对体系力学性能、结构形态和粘弹行为的影响。结果表明:PU/PMMA是呈两相结构的部分相容体系,其中线型共混物伸长率最大,IPN强度最高,而嵌段共聚物的力学性能较差。此外,嵌段共聚物和IPN光固化体系形成的相畴结构均一,其抗张强度和伸长率明显高于热固化体系。聚合物的力学性能除了受化学结构影响以外,还与化学组成有关,随体系中PMMA含量和PU中硬链段含量增加,聚合物抗张强度升高,伸长率下降。     

聚甲基丙烯酸甲酯与聚醋酸乙烯酯共混的红外光谱研究

用红外光谱(FTIR)研究了聚甲基丙烯酸甲酯(PMMA)与聚醋酸乙烯酯(PVAc)共混体系相容性,在160℃以上共混体系发生相分离;分相体系与非分相体系的FTIR谱明显不同;共混体系的FTIR谱不能从两统组分红外光谱简单加和得到;结果表明大分子构象发生了变化,PMMA/PVAc体系相容可能是大分子构象熵变所致。     

用透射电镜法研究聚(苯乙烯-异戊二烯)二嵌段共聚物微相分离的微区尺寸

本文采用透射电镜(TEM)法,系统地研究了具有不同组成,不同分子量和不同形态结构的聚(苯乙烯-异戊二烯)二嵌段共聚物,并由TEM照片直接测量具有栓状,层状和有规双连续双金钢石(OBDD)结构的PS-PI二嵌共聚物的微区尺寸,讨论了其与分子量的关系。实验证明嵌段共聚物微相分离有规结构的微区尺寸大小与分子量呈2/3的关系。     

嵌段共聚物／均聚物共混体系的微相分离和形态结构研究

着重介绍嵌段共聚物／均聚物共混体系的微相分离，微胶束的形成，微区的形态结构以及形态的控制。     

壳聚糖-聚羟基丁酸酯共混膜的制备与性质

以乙酸为共溶剂,制备了壳聚糖-聚羟基丁酸酯(CTS-PHB)共混膜,利用红外光谱(FT-IR)、广角X粉末衍射(WAXD)、扫描电镜(SEM)及差热分析(DTA)表征了共混膜的化学组成、晶形、形貌和热稳定性能。研究表明:CTS和PHB可在体积百分数为62.5%的乙酸溶液中共混,形成表面光滑、不透明的膜,干态共混膜具备一定的力学强度。各比例的CTS-PHB共混膜有相同的热分解温度,共混膜的形貌特征随两组分质量配比变化,其中mPHB/mCTS=1/1的共混膜显示出良好的有序结构。     

SEBS-g-MAH对LLDPE结晶行为的影响

利用差示扫描量热法结合Avrami方程研究了线性低密度聚乙烯（LLDPE）、LLDPE与苯乙烯-乙烯-丁烯-苯乙烯嵌段共聚物（SEBS）共混体系及LLDPE与不同接枝率的SEBS共聚物接枝马来酸酐（SEBS-g-MAH）共混体系的非等温结晶动力学,探讨了SEBS-g-MAH对LLDPE结晶行为的影响。通过偏光显微镜（POM）观察了各体系的结晶形态。通过Gupta法、Jeziorny法和莫志深法分别对非等温结晶过程进行表征,结果显示：热塑性弹性体SEBS及其接枝物SEBS-g-MAH的加入阻碍了LLDPE分子链的规则排列,影响了链段在结晶扩散迁移过程中的规整排列速率,使得结晶速率变慢,对LLDPE晶体生长起了抑制作用。样品的Avrami指数均为1.1～1.5,说明LLDPE的结晶成核机理和生长方式没有改变。     

PCL-PEG-PCL/PLA共混材料的制备与性能分析

为了拓宽聚乳酸（PLA）在生物医学领域的应用,使用少量钛酸异丙酯改性相对分子质量为2 000的聚乙二醇（PEG-2000）引发己内酯开环聚合得到相对分子质量为6 000的生物可降解三嵌段共聚物聚己内酯-聚乙二醇-聚己内酯（PCEC）,分别将PCEC、PEG-6000与PLA共混,考察其微观形貌、结晶性能、力学性能的区别。结果显示PCEC/PLA共混物的微观形貌是典型的"海岛"结构;在相同配比下,PCEC促进PLA结晶的能力要小于PEG-6000。当PCEC和PLA的质量比为15：85时,PCEC/PLA共混物的断裂伸长率最佳,相同质量比下的PEG-6000/PLA共混物的断裂伸长率比PCEC/PLA共混物的断裂伸长率要高7%,而拉伸强度要低50%。     

聚醚聚酯嵌段共聚物的表面性质对血液相容性的影响

聚合物的表面性质和结构对血液相容性具有很大的影响。本文通过接触角、吸水率和电子能谱研究了聚醚聚酯嵌段共聚物混合物的表面组成及微相分离结构。电子能谱的测试表明:试样空气面的氧碳元素比高于试样本体,表明醚键向空气面扩散,并以此来估量试样空气面的组成分布。试样的血液相容性与试样空气面氧碳比的提高程度随试样中聚乙二醇对苯二甲酸酯(PEGT)组成的递增呈相似的变化趋势,在共混物中软链段的组分比:聚四亚甲基二醇对苯二甲酸酯/聚乙二醇对苯二甲酸酯(PTMGT/PEGT)=60/40时,试样的接触角最大、氧碳比的提高率最大、血液相容性最好,且试样呈现最为细微的相分离结构。由此表明聚醚聚酯嵌段共聚物混合物的血液相容性主要受表面组成、各链段的表面自由能及微相分离程度的影响。     

APPLICATION OF LORNOXICAM TO PATIENT-CONTROLLED ANALGESIA IN PATIENTS UNDERGOING ABDOMINAL SURGERIES

FOR anesthesiologis s ,treatingpostoperativepainhas alwaysbeen a problem.Althoughopioidshave been provedtobe effective,theirsideeffectscouldnotbeignored.With thedevelopmentofscienceand pharmacology,many drugs with aspectsof satisfactoryanalgesicefficacyand couldbe welltoleratedby patientshave been developed.And lornoxicamisone of them, which isa non-steroidalanti-inflammatorydrug (NSAID ), with analgesic, anti-infl-ammatory,andantipyreticproperties.Itseliminationhalf-time(3 to 5 hours) isle…     

Dr.Zhang Ren''''s Experience in the Acupuncture Treatment of Different Diseases with the Same Therapeutic Principle

Dr.Zhang Ren,the chief physician,is the chairman of Shanghai Acupuncture and Moxibustion Association.Having been engaged in medicine for about 40 years,he is experienced in treating various intractable diseases.In his long years of clinical practice,he advocates taking the TCM differentiation as the basis to seek for the acupuncture method for treatment of modern intractable diseases.The author of this essay had the fortune to follow Dr.Zhang in study.The following is a summary of Dr.Zhang's experience in the acupuncture treatment for different intractable diseases with the same therapeutic principle.     

Luo Lingjie''''s Experience in Treating Chronic Nephropathy

In treating chronic nephropathy,Luo Lingjie,a chief physician,pays attention to regulating the balance between yin and yang,treating infection if present,and removing pathogenic factors.He prescribes gentle drugs and uses carefully strongly warming-tonifying ones,emphasizes the importance of persuading the patient to persist in treatment with medication and nurse one's health for recuperation,and is good at combined use of TCM and western medicine therapy and brings the merits of various therapies into full play,with obvious theraoeutic effects.     

Acupuncture Combined with Spinal Tui Na for Treatment of Primary Dysmenorrhea in 30 Cases

Objective: To observe the therapeutic effects in acupunture treatment of primary dysmenorrhea combined with spinal Tui Na, and study its mechanism. Methods: Thirty cases of the treatment group were treated by acupuncture combined with spinal Tui Na, and thirty cases in the control group were treated by routine acupuncture. Results: The total effective rate was 93.3% in the treatment group, and 73.3% in the control group, with a significant difference between the two groups (P<0.05). Conclusions: Acupuncture combined with spinal Tui Na has good prospects for treatment of primary dysmenorrhea.     

猪肺磷脂注射液联合经鼻持续气道正压通气对呼吸衰竭早产儿的临床疗效及肌酸激酶同工酶活性的影响

目的 探讨猪肺磷脂注射液联合经鼻持续气道正压通气(NCPAP)对呼吸衰竭早产儿的临床疗效及肌酸激酶同工酶活性(CK-MB)的影响.方法 选取呼吸衰竭早产儿80例,分为观察组和对照组各40例.对照组采用NCPAP给氧治疗,观察组给予NCPAP给氧联合猪肺磷脂气管内给药.观察两组患儿治疗前及治疗12h、24 h后PaO2、PaCO2、血氧饱和度(SaO2)、pH的变化情况,检测治疗前及治疗5d后血清CK-MB水平;评估两组患儿的临床治疗效果.结果 两组患儿PaO2、PaCO2、SaO2、pH比较,差异均有统计学意义(P＜0.05),其中观察组治疗后的PaO2、SaO2、pH均高于对照组,PaCO2则低于对照组.两组的PaO2、SaO2、pH均随观察时间延长而升高(P＜0.05),PaCO2均随观察时间的延长而降低(P＜0.05).观察组治疗有效率为87.5％,显著高于对照组的70.0％ (P ＜0.05).治疗5d后两组患儿血清CK-MB水平均较前降低(P＜0.05),且观察组明显低于对照组(P＜0.05).结论 猪肺磷脂注射液气管内给药联合NCPAP可以显著降低呼吸衰竭早产儿CK-MB的含量,提高治疗有效率,起到很好的呼吸循环支持作用.     

Survey and practice of reporting quality of randomized controlled clinical trials on traditional Chinese medicine

Evidence obtained from randomized controlled trials （RCTs） has been generally accepted as the gold standard in the evaluation of clinical effectiveness. Readers need to understand the trial design, implementation, results, analysis and interpretation, so as to fully Jnderstand the results of RCTs. Thus, the investigators of RCTs have to report these items in a complete, accurate and clear manner. Since 1998, we have conducted several evaluations on the reporting quality of RCTs published in Chinese journals on traditional Chinese medicine （TCM） and results have shown that there is an urgent need for higher quality RCTs on TCM.     

TCM Treatment of Ankylosing Spondylitis by Tonifying the Kidney and Strengthening the Governor Vessel

Ankylosing spondylitis is a chronic and progressive disorder with inflammation mainly involving the central axis joints. It mainly affects the cervical spine and the lumbosacral area, with the pathogenesis closely related to the kidney and the Governor Vessel (GV). TCM holds that the syndrome is deficiency in origin and excess in superficiality, which is due to insufficiency of the kidney, deficiency of GV, and blocking of the channels with the invasion of exogenous evil, leading to poor circulation of qi and blood and malnutrition of the bones, muscles and joints. The TCM method of tonifying the kidney and strengthening GV to regulate circulation of qi and blood and check the arthralgia pain should be adopted, with the Kidney-Tonifying and GV Strengthening Decoction (益肾强督汤) prescribed.     

IMPROVING P-gp EXPRESSION IN HUMAN MONONUCLEAR CELLS IN VITRO TRANSFECTED BY MULTIDRUG RESISTANCE-1 mRNA

CHEMOTHERAPY playsa greatrolein the treat- ment of malignanttumors,especiallyingynecolo- gicalones.But inanticancerchemotherapy,leuko-cytopeniaisfrequentlytheprimarydose-limitingsideeffect factor.Moreover,cancersarefrequentlychemoresistantbe-causeof overexpressionof P-glycoprotein(P-gp), which isencodedby multidrugresistancegene (MDR1 ) and detectableinup to50% ofhuman cancersand renderscellsresistancetoanticancerdrugs.The safetyand potentialtherapeuticbenefitof mdr1 gene transferredto h…